VYNE Therapeutics Inc. (NASDAQ:VYNE – Get Free Report) saw unusually-strong trading volume on Monday . 15,572 shares were traded during trading, an increase of 55% from the previous session’s volume of 10,032 shares.The stock last traded at $25.20 and had previously closed at $25.45.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of VYNE Therapeutics in a research report on Monday, May 4th. Three equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, VYNE Therapeutics currently has a consensus rating of “Reduce”.
View Our Latest Stock Analysis on VYNE
VYNE Therapeutics Price Performance
VYNE Therapeutics (NASDAQ:VYNE – Get Free Report) last posted its quarterly earnings data on Friday, May 15th. The company reported ($4.00) earnings per share for the quarter, topping analysts’ consensus estimates of ($9.00) by $5.00. The company had revenue of $0.09 million during the quarter, compared to analysts’ expectations of $0.20 million. VYNE Therapeutics had a negative return on equity of 70.42% and a negative net margin of 4,726.21%. On average, analysts anticipate that VYNE Therapeutics Inc. will post -1.1 earnings per share for the current year.
VYNE Therapeutics Announces Dividend
The company also recently disclosed a special dividend, which was paid on Thursday, July 23rd. Shareholders of record on Wednesday, July 22nd were paid a $19.00 dividend.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in VYNE. XTX Topco Ltd purchased a new position in VYNE Therapeutics during the fourth quarter worth about $46,000. Rangeley Capital LLC boosted its holdings in VYNE Therapeutics by 18.1% in the 1st quarter. Rangeley Capital LLC now owns 118,064 shares of the company’s stock valued at $71,000 after purchasing an additional 18,064 shares in the last quarter. Two Sigma Investments LP acquired a new position in VYNE Therapeutics during the 3rd quarter worth approximately $74,000. Geode Capital Management LLC increased its position in VYNE Therapeutics by 64.2% during the 4th quarter. Geode Capital Management LLC now owns 225,152 shares of the company’s stock worth $131,000 after purchasing an additional 88,030 shares during the period. Finally, ADAR1 Capital Management LLC purchased a new position in shares of VYNE Therapeutics during the 4th quarter worth approximately $147,000. 83.78% of the stock is currently owned by institutional investors and hedge funds.
About VYNE Therapeutics
VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.
The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.
Featured Articles
- Five stocks we like better than VYNE Therapeutics
- AMD’s AI Bubble Could Burst Into Explosive Upside
- Atlassian’s AI Pivot Is Starting to Challenge Wall Street’s Bear Case
- Apple’s Earnings Setup Puts Its Record Rally and AI Patience to the Test
- Oil Prices Are Surging and These 4 Stocks Are Cashing In
Receive News & Ratings for VYNE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VYNE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
